Advertisement
Canada markets open in 5 hours 15 minutes

  • S&P/TSX

    21,885.38
    +11.66 (+0.05%)
     

  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     

  • DOW

    38,085.80
    -375.12 (-0.98%)
     

  • CAD/USD

    0.7332
    +0.0009 (+0.12%)
     

  • CRUDE OIL

    84.03
    +0.46 (+0.55%)
     

  • Bitcoin CAD

    87,845.36
    +444.77 (+0.51%)
     

  • CMC Crypto 200

    1,387.77
    -8.76 (-0.63%)
     

  • GOLD FUTURES

    2,358.30
    +15.80 (+0.67%)
     

  • RUSSELL 2000

    1,981.12
    -14.31 (-0.72%)
     

  • 10-Yr Bond

    4.7060
    +0.0540 (+1.16%)
     

  • NASDAQ futures

    17,756.00
    +188.50 (+1.07%)
     

  • VOLATILITY

    15.51
    +0.14 (+0.91%)
     

  • FTSE

    8,119.95
    +41.09 (+0.51%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • CAD/EUR

    0.6826
    +0.0005 (+0.07%)
     

Analyzing Sangamo Therapeutics’ Operational Performance

Kenneth Smith
Updated
Analyzing Sangamo Therapeutics’ Operational Performance

Sangamo Therapeutics (SGMO) incurred general and administrative expenses of $10.99 million in the third quarter of 2018, compared with $6.42 million in the third quarter of 2017. The fiscal 2018 research and development expenses for peers Amgen (AMGN), Biogen (BIIB), and Gilead Sciences (GILD) are expected at $3.52 billion, $2.48 billion, and $3.71 billion, respectively. Sangamo Therapeutics’ net interest and other income grew from $681,000 in the third quarter of 2017 to $3.4 million in the latest quarter.

Continue reading